211 related articles for article (PubMed ID: 36724109)
1. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
[No Abstract] [Full Text] [Related]
2. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
[TBL] [Abstract][Full Text] [Related]
3. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: Pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program.
Epperson CN; Rubinow DR; Meltzer-Brody S; Deligiannidis KM; Riesenberg R; Krystal AD; Bankole K; Huang MY; Li H; Brown C; Kanes SJ; Lasser R
J Affect Disord; 2023 Jan; 320():353-359. PubMed ID: 36191643
[TBL] [Abstract][Full Text] [Related]
4. Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Clayton AH; Lasser R; Nandy I; Sankoh AJ; Jonas J; Kanes SJ
J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36811520
[No Abstract] [Full Text] [Related]
5. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
[TBL] [Abstract][Full Text] [Related]
6. Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
[TBL] [Abstract][Full Text] [Related]
7. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J; Yang L; Yang G; Gao J
Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.
Kato M; Nakagome K; Baba T; Sonoyama T; Okutsu D; Yamanaka H; Shimizu R; Motomiya T; Inoue T
Psychiatry Clin Neurosci; 2023 Sep; 77(9):497-509. PubMed ID: 37252829
[TBL] [Abstract][Full Text] [Related]
11. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
[TBL] [Abstract][Full Text] [Related]
14. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
Ahmad A; Awan AR; Nadeem N; Javed AS; Farooqi M; Daniyal M; Mumtaz H
Front Neurosci; 2024; 18():1361692. PubMed ID: 38726035
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
Cutler AJ; Mattingly GW; Kornstein SG; Aaronson ST; Lasser R; Zhang H; Rana N; Brown C; Levin S; Miller C; Kotecha M; Forrestal F; Doherty J
J Clin Psychiatry; 2023 Dec; 85(1):. PubMed ID: 38153320
[No Abstract] [Full Text] [Related]
16. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Henigsberg N; Mahableshwarkar AR; Jacobsen P; Chen Y; Thase ME
J Clin Psychiatry; 2012 Jul; 73(7):953-9. PubMed ID: 22901346
[TBL] [Abstract][Full Text] [Related]
17. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
Barnes KN; Vogl CM; Nelson LA
Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
Sheehan DV; Rozova A; Gossen ER; Gibertini M
Psychopharmacol Bull; 2009; 42(4):5-22. PubMed ID: 20581790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]